Welcome to our dedicated page for Fusion Pharmaceuticals news (Ticker: FUSN), a resource for investors and traders seeking the latest updates and insights on Fusion Pharmaceuticals stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Fusion Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Fusion Pharmaceuticals's position in the market.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Fusion Pharmaceuticals (NASDAQ: FUSN), a clinical-stage oncology company, has announced a presentation at the Bloom Burton & Co. Healthcare Investor Conference on April 25, 2023, at 3:00 p.m. ET. The presentation will be delivered by John Valliant, Ph.D., the Chief Executive Officer. Investors can access a live webcast of the presentation on the Company's website, with a replay available for 90 days.
Fusion specializes in developing next-generation radiopharmaceuticals, aiming to deliver targeted cancer therapies. Their clinical pipeline includes several trials targeting various cancers, including those resistant to traditional therapies. Recent collaborations with AstraZeneca and Merck highlight Fusion's commitment to advancing cancer treatment through innovative approaches.
Fusion Pharmaceuticals (Nasdaq: FUSN) presented preclinical data supporting its clinical-stage FPI-2059, a targeted alpha therapy (TAT) aimed at neurotensin receptor 1 (NTSR1), at the AACR Annual Meeting. The data indicated that FPI-2059 effectively inhibits tumor growth in colorectal cancer models, showing strong tumor uptake and dose-dependent efficacy. Additional research highlighted the potential of targeting tumor endothelial marker 1 (TEM-1) and epidermal growth factor receptor variant 3 (EGFRvIII) for future TAT applications. The positive results from these studies underscore the company's ongoing Phase 1 study for FPI-2059 and its commitment to developing next-generation radiopharmaceuticals.
Fusion Pharmaceuticals (FUSN) announced the FDA clearance of IND applications for FPI-2068 and imaging analogue FPI-2107. FPI-2068 is a bispecific targeted alpha therapy (TAT) aimed at delivering actinium-225 to tumors expressing EGFR and cMET, validated targets in cancer treatment. This IND filing marks a critical milestone in the development collaboration with AstraZeneca (AZN), indicating plans for a Phase 1 clinical study. The therapy is intended to enhance tumor specificity and patient screening using corresponding imaging isotopes, potentially increasing therapeutic response rates. The development will be shared equally between Fusion and AstraZeneca through clinical phases, with Fusion managing the initial trial.
Fusion Pharmaceuticals Inc. (NASDAQ: FUSN) announced on April 5, 2023, that its Board of Directors granted stock option awards to purchase 258,000 shares to four employees outside of the company's 2020 Stock Option and Incentive Plan. These options, priced at $3.80 per share, align with the closing price on April 3, 2023, and will vest over four years. Fusion is a clinical-stage oncology company specializing in next-generation radiopharmaceuticals, with key clinical trials underway targeting various cancers, including metastatic castration-resistant prostate cancer. The company has collaborations with AstraZeneca and Merck for innovative therapies. This move reflects Fusion's commitment to attracting talent as it advances its clinical pipeline.
Fusion Pharmaceuticals (Nasdaq: FUSN) has announced the first patient dosing in a Phase 1 study for [225Ac]-FPI-2059, a targeted alpha therapy aimed at treating solid tumors with neurotensin receptor 1 (NTSR1). The therapy targets tumors overexpressing NTSR1, seen in various cancers. The trial aims to assess the safety, tolerability, and early efficacy of FPI-2059. This marks Fusion's fourth clinical program, showcasing their potential in the radiopharmaceutical market. With promising early data from prior studies, the company is set to advance its pipeline of innovative therapies.